fig6

Figure 6. Translational roadmap for advancing ADSL-targeted strategies in PDAC. Future development of ADSL-directed therapy will require integration of mechanistic, biomarker, and preclinical validation studies. Key priorities include the design of potent and tumor-selective ADSL inhibitors, identification of predictive biomarkers such as SAICAR/AICAR ratios or fumarate-associated signatures, and validation in orthotopic and immunecompetent PDAC models. This framework highlights how ADSL may be advanced from a mechanistic metabolic target to a clinically actionable vulnerability in precision oncology. ADSL: Adenylosuccinate lyase; PDAC: pancreatic ductal adenocarcinoma; SAICAR: succinylaminoimidazole carboxamide ribotide; AICAR: aminoimidazole carboxamide ribotide; AMP: adenosine monophosphate.